Unimed Pharmaceuticals
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Unimed Pharmaceuticals
Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend
M&A edition: Mergers by Century/Clade, Eliem/Tenet, Kintara/TuHURA, Aditxt/Appili, Onconova/Traws and Apotex/Searchlight follow other companies joining forces in a tight cash environment.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
‘Indomitable Spirit’ Spurs Incontinence Treatment Firm Axena
Axena Health recently secured a HCPCS code for its female incontinence device Leva. For CEO Eileen Maus, this is just the latest in a string of successes across the women’s health, or femtech, sector.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice